Skip to main content
Bladder CancerDiagnostics and screening

What this study is

Voided urinary cytology (VUC) is the most widely used urine-based assay for detecting bladder cancer (BCa); however, it fails to detect approximately 50% of low-grade or early stage BCa when it is most curable. Furthermore, the detection rate of VUC for recurrent BCa is not much better. Because of this severe limitation, all patients who are under surveillance to monitor for recurrent BCa must undergo an invasive examination of the urinary bladder, where a miniature camera is inserted into the bladder and the bladder inspected (cystoscopy). We propose to improve the non-invasive detection of recurrent BCa by further validating a multiplex ELISA assay directed at a BCa-associated diagnostic signature in voided urine samples.

Study details

Sponsor
Cedars-Sinai Medical Center
Conditions
Bladder Cancer
Enrolling
300 people
Starts
2016-12-30
Est. completion
2028-08
Record
View on ClinicalTrials.gov ↗